IRAK 4 Inhibitor (PF-06650833) in Hospitalized Patients With COVID-19 Pneumonia and Exuberant Inflammation.
Status:
Recruiting
Trial end date:
2022-05-06
Target enrollment:
Participant gender:
Summary
The aim of the current clinical study is to evaluate the efficacy and safety of inhibition of
Interleukin-1 receptor associated kinase 4 (IRAK4) in ameliorating the proinflammatory state
and improving outcomes in severe COVID-19.